Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …

The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global
public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug …

Background. A large increase in multi-drug-resistant Acinetobacter baumannii, especially
carbapenem-resistant strains, occurred during the first two years of the COVID-19 pandemic …

Introduction The increasing prevalence of infections with multidrug-resistant (MDR),
extensively-drug resistant (XDR) or difficult-to-treat drug resistant (DTR) Gram-negative …

Aminoglycosides are a family of rapidly bactericidal antibiotics that often remain active
against resistant Gram-negative bacterial infections. Over the past decade, their use in …

Polymyxins are commonly used as the last resort for the treatment of MDR Acinetobacter
baumannii and Klebsiella pneumoniae nosocomial infections; however, apart from the …

Evidence-based, standard antibiotic therapy for ventilator-associated pneumonia (VAP)
caused by carbapenem-resistant Acinetobacter baumannii (CRAB) is a relevant unmet …

Introduction: Acinetobacter baumannii (AB) is a multidrug-resistant pathogen commonly
associated with nosocomial infections. The resistance profile and ability to produce biofilm …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) is resistant to
major antibiotics such as penicillin, cephalosporin, fluoroquinolone and aminoglycoside …

Carbapenem-resistant Acinetobacter baumannii (CRAB) is a worldwide non-fermenting
Gram-negative bacillus responsible for potentially severe nosocomial infections, especially …